Julie Tibbets chairs Goodwin’s FDA practice and is a co-chair of the Late-Stage Drug Development practice at Goodwin, which is a global law firm with a core focus in technology and life sciences. She focuses her practice on FDA-regulated product development, clinical research, regulatory crisis resolution, product marketing and corporate communications as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product areas of focus include biologics, drugs, medical devices, in vitro diagnostics, as well as digital therapeutics, tools and apps. Julie has been practicing FDA law nearly 20 years and has been named a leading pharmaceutical and medical product regulatory attorney by Chambers USA, LMG Life Sciences, and The Best Lawyers in America.